摘要
目的:探讨与分析影响两种治疗法治疗无法切除的中晚期肝癌患者长期生存的原因。方法:27例无法切除的中晚期肝癌,Ⅲ期10例占37.1%,Ⅱ～Ⅲ期17例占62.9%,合并2～3种以上严重疾病者24例,占88.9%,肝癌灶最大直径13cm,最小直径6.5cm,肝癌多发灶(5个/3cm×2.6cm×2.4cm)1例。PCTI乙醇及凝血酶2次+TACE治疗1次者7例;PCTI γ-INF、TNF、乙醇及凝血酶2次+TACE1次者5例;PCTI SST及上述药物治疗3次+TACE治疗1次者6例;PCTI卡铂、紫杉醇、SST、γ-INF、TNF、乙醇及凝血酶3次+TACE治疗2次者6例;PCTI应用上述药物治疗7次+TACE治疗3次者3例。结果:生存期最长者426天,最短者241天;生存期最长者634天,最短者368天;生存期最长者869天,最短者612天;生存期最长者1461天,最短者873天;生存期最长者2556(7年以上)天,最短者1096天。结论:无法切除的中晚期肝癌合并肝炎后肝硬化、门脉高压症以及严重心肺肾疾病是影响其疗效的根源,两种介入法联合治疗的次数与多种用药的次数是影响其疗效的重要因素。
Objective： To discuss and analyze the factors affecting long-term survival after simultaneous treatment with 2 kinds of therapy for patients with unresectable mid and late stage liver cancer. Methods： Twenty-seven cases had unresectable mid and late stage liver cancer. The 10 cases in stage II accounted for 37.1%; 17 cases in stages II -III accounted for 62.9%; diseases affecting 2 or more important organs were 24 cases, accounting for 88.9%. The liver cancer focus diameters were 9.5-13 cm; 1 case of liver cancer that had a focus diameter of 5.3x2.6x2.4 cm accounted for 3.7%. Treatments were as follows： （1） PCTI, ethyl alcohol and zymoplasm 2 ＋TACE was given 1 time （7 cases）; （2） PCTI, r-INF, TNF, ethyl alcohol and zymoplasm 2 ＋TACE was given 1 time （5 cases）; （3） PCTI, SST and above pharmacological treatment 3 ＋ TACE was given 1 time （6 cases）; （4） PCTI card platinum, taxus mellow, SST, r-INF, TNF, ethyl alcohol and zymoplasm 3 ＋ TACE was given 2 times （6 cases）; （5） PCTI applied above pharmacological treatment 7 ＋TACE was given 3 times （3 cases）. Results： For each treatment group survival time was as follows： （1） Max. 426 days, min. 241 days; （2） max 634 days, min. 368 days; （3） max. 869 days, min. 612 days; （4） max 1461 days, min. 873 days; （5） max. 2,556 days （above 7 years）, min. 1096 days. Conclusion： The main factors for curative effects include unresectable mid and late stage liver cancer oc- curring with hepatitis, liver cirrhosis, the portal vein hyperbarism and serious cardiopulmonary kidney disease. Moreover, the number of therapies used simultaneously, as well as the number of multiple medications, are also important factors affecting the cure of this disease.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2010年第12期710-712,共3页
Chinese Journal of Clinical Oncology
